A Pilot Study of the Novel Antiretroviral Combination of Atazanavir and Raltegravir in HIV-1 Infected Subjects With Virologic Suppression on a Standard Regimen of Boosted Atazanavir, Tenofovir and Emtricitabine
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Enrollment
- 43
- Locations
- 9
- Primary Endpoint
- Maintenance of Virologic Suppression
Study Overview
Brief Summary
The purpose of this Phase IV pilot study is to evaluate the safety, tolerability, and satisfaction of a nucleoside analog reverse-transcriptase inhibitors (NRTI)sparing regimen for participants fully suppressed on an atazanavir/ritonavir based highly active antiretroviral therapy (HAART)regimen plus emtricitabine/tenofovir (Truvada). Several pharmacologic factors support this concept including the favorable drug interaction between atazanavir and raltegravir. Participants will be randomized to either continue on their current regimen or one of two study arms (atazanavir 300mg plus ritonavir 100mg daily plus raltegravir 400mg twice daily or atazanavir 300mg twice daily plus raltegravir 400mg twice daily). Participants will be followed for 48 weeks for safety, tolerability, and satisfaction. After baseline, the participants will have six clinic visits for evaluation and labs.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •HIV-1 infection
- •Treatment with a stable antiretroviral regiment containing boosted atazanavir, tenofovir and emtricitabine at screen and for at least 90 days prior to screening
- •No plan to make changes to HIV treatment regimen (other than those required by the study) in the next 48 weeks
- •Undetectable HIV RNA at screening AND no HIV RNA>200 copies during the 180 day period prior to screening
- •CD4 count>200
- •No evidence of resistance to any of the drugs in any of the 3 arms, if prior resistance tests are available
- •Subjects who, in the opinion of their treating physicians, would be candidates to switch antiretroviral medications
- •Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 8 weeks after the last dose of study drug
- •Ability and willingness to provide written informed consent and comply with protocol requirements
Exclusion Criteria
- •Prior exposure to raltegravir or elvitegravir
- •Women who are pregnant, breast-feeding, or with a positive pregnancy test
- •Sexually active fertile men not using effective birth control if their female partners are of child-bearing potential
- •Women of child-bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks after the last dose of study drug
- •Life expectancy less than 6 months
- •Presence of any currently active AIDS defining conditions with the exception of stable cutaneous Kaposi's sarcoma
- •Treatment with proton-pump inhibitor or H2-receptor antagonist
- •ECG demonstrating atrioventricular block, prolonged QRS interval greater than 12 ms, or known complete bundle branch block
- •Acute or chronic hepatitis B infection as evidenced by presence of hepatitis B surface antigen and absence of hepatitis B surface antibody
- •Clinical or laboratory evidence of significantly decreased hepatic function of decompensation irrespective of liver enzyme levels
- •Prisoners or subjects who are involuntarily incarcerated
- •Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness
Arms & Interventions
Intervention Arm No.1
Intervention: atazanavir/raltegravir (Drug)
Intervention Arm No.2
Intervention: atazanavir/raltegravir (Drug)
Control Arm
Continue baseline regimen
Intervention: atazanavir/tenofovir/emtricitabine (Drug)
Outcomes
Primary Outcomes
Maintenance of Virologic Suppression
Time Frame: 48 weeks
To evaluate and compare maintenance of virologic suppression with raltegravir (RAL) 400mg 2x daily plus atazanavir (ATV) dosed either as ATV/ritonavir (RTV)300/100mg 1x daily or ATV 300mg 2x daily in subjects with virologic suppression on a standard regimen of ATV/RTV plus Truvada. Virologic suppression is defined as HIV RNA \< 40 copies/mL.
Secondary Outcomes
- Change in Quality of Life From Baseline to 48 Weeks of Study Treatment(baseline and 48 weeks)
- The Difference in CD4 From Baseline to Week 48(Baseline and Week 48)
- The Change in Adherence to Study Treatment Arm From Baseline to Week 48(Baseline and Week 48)